Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126489261 | 12648926 | 1 | I | 20160802 | 20160812 | 20160812 | EXP | E2B_00579055 | CA-HQ SPECIALTY-CA-2016INT000764 | INTERCHEM | 63.00 | YR | F | Y | 0.00000 | 20160812 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126489261 | 12648926 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 20 MG | U | 201749 | 20 | MG | |||||||
| 126489261 | 12648926 | 2 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 20 MG | U | 201749 | 20 | MG | |||||||
| 126489261 | 12648926 | 3 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 7.1429 MG (50 MG,1 IN 1 W) | U | 0 | 50 | MG | |||||||
| 126489261 | 12648926 | 4 | SS | METHOTREXATE. | METHOTREXATE | 1 | Subcutaneous | 20 MG | U | 0 | 20 | MG | |||||||
| 126489261 | 12648926 | 5 | SS | METHOTREXATE. | METHOTREXATE | 1 | Subcutaneous | 20 MG | U | 0 | 20 | MG | |||||||
| 126489261 | 12648926 | 6 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | Unknown | UNK | U | 0 | |||||||||
| 126489261 | 12648926 | 7 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | Unknown | UNK | U | 0 | |||||||||
| 126489261 | 12648926 | 8 | SS | NEORAL | CYCLOSPORINE | 1 | Unknown | UNK | U | 0 | |||||||||
| 126489261 | 12648926 | 9 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | 3 MG/KG | U | 0 | 3 | MG/KG | |||||||
| 126489261 | 12648926 | 10 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | 8 MG/KG | U | 0 | 8 | MG/KG | |||||||
| 126489261 | 12648926 | 11 | SS | ORENCIA | ABATACEPT | 1 | Subcutaneous | 125 MG | U | 0 | 125 | MG | |||||||
| 126489261 | 12648926 | 12 | SS | CYCLOSPORIN | CYCLOSPORINE | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126489261 | 12648926 | 1 | Rheumatoid arthritis |
| 126489261 | 12648926 | 3 | Rheumatoid arthritis |
| 126489261 | 12648926 | 4 | Rheumatoid arthritis |
| 126489261 | 12648926 | 6 | Rheumatoid arthritis |
| 126489261 | 12648926 | 8 | Product used for unknown indication |
| 126489261 | 12648926 | 9 | Rheumatoid arthritis |
| 126489261 | 12648926 | 10 | Rheumatoid arthritis |
| 126489261 | 12648926 | 11 | Rheumatoid arthritis |
| 126489261 | 12648926 | 12 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126489261 | 12648926 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126489261 | 12648926 | Arthralgia | |
| 126489261 | 12648926 | Drug ineffective | |
| 126489261 | 12648926 | Joint swelling | |
| 126489261 | 12648926 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126489261 | 12648926 | 1 | 2000 | 2015 | 0 | |
| 126489261 | 12648926 | 2 | 2015 | 0 | ||
| 126489261 | 12648926 | 3 | 200311 | 200401 | 0 | |
| 126489261 | 12648926 | 4 | 2000 | 2015 | 0 | |
| 126489261 | 12648926 | 5 | 2015 | 0 | ||
| 126489261 | 12648926 | 6 | 2000 | 2015 | 0 | |
| 126489261 | 12648926 | 8 | 2000 | 2015 | 0 | |
| 126489261 | 12648926 | 9 | 2002 | 2013 | 0 | |
| 126489261 | 12648926 | 10 | 201207 | 201209 | 0 | |
| 126489261 | 12648926 | 11 | 201301 | 201311 | 0 |